newsFirst AI-generated small molecule drug enters Phase II trial29 June 2023 | By Catherine Eckford (European Pharmaceutical Review)Insilico Medicine’s novel AI-generated small molecule inhibitor drug represents a new milestone in pharmaceutical drug development.
newsEMA human medicines committee (CHMP) highlights, November 202214 November 2022 | By Catherine Eckford (European Pharmaceutical Review)The Committee for Medicinal Products for Human Use (CHMP)’s November meeting consisted of approval recommendations for four medicines, including a biosimilar for osteoporosis and a new COVID-19 vaccine.
newsTrial data reveals potential new treatment for pulmonary fibrosis patients19 May 2022 | By Sarah Wills (European Pharmaceutical Review)The data from the 12 week trial showed phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 showed a reduction in the rate of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).
newsEMA’s human medicines committee (CHMP) April 2022 meeting highlights29 April 2022 | By European Pharmaceutical ReviewAt its latest meeting, EMA’s human medicines committee (CHMP) recommended the approval of four medicines, seven extensions of therapeutic indication and laid out recommendations for diabetes treatment outside of the EU.
newsBiotech company Promedior merges with Roche19 February 2020 | By European Pharmaceutical ReviewRoche has successfully completed its purchase of Promedior, Inc. along with its entire portfolio of fibrotic disease therapeutics.
newsCypralis granted new Innovate UK feasibility stage award for chronic pancreatitis18 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)Cypralis, has been awarded funding by Innovate UK to develop cyclophilin inhibitors targeting fibrotic diseases...
newsFirst patient enrolled in IPF biomarker study of Ofev30 June 2016 | By Victoria White, Digital Content ProducerINMARK is a study investigating the effect of Ofev (nintedanib) on changes in specific blood biomarkers in patients with idiopathic pulmonary fibrosis...
newsMerck enters the IPF market through Afferent acquisition27 June 2016 | By Victoria White, Digital Content ProducerMerck’s acquisition of Afferent Pharmaceuticals will provide it with an entry-platform into the fast-growing IPF market, according to GlobalData...
newsIPF market will grow to $3.2 billion by 2025, says GlobalData21 June 2016 | By Victoria White, Digital Content ProducerThe idiopathic pulmonary fibrosis (IPF) market will rise substantially from just over $900 million in 2015 to $3.2 billion by 2025, according to GlobalData...
